Qianjin Pharmaceutical

Zhuzhou Qianjin Pharmaceutical Co., Ltd. was founded in 1966, underwent shareholding reform in 1993, and was listed on the Shanghai Stock Exchange in 2004 (stock code: 600479). In 2005, the 'Qianjin' trademark was recognized as a China Well-known Trademark by the State Administration for Industry and Commerce. The company has 13 wholly-owned subsidiaries and over 4,000 employees. The company currently has eight dosage forms including tablets, granules, and capsules, with 13 production lines and an annual production capacity of 3 billion yuan. Main products include Fuke Qianjin Tablets (Capsules), Buxue Yimu Granules, Chunru Gel, Duanhongyin Capsules, and other 14 exclusive varieties, with more than 200 patents and over 50 production approvals. Among them, Fuke Qianjin Tablets (Capsules) are a national secret technology project, a national essential drug, a Class A variety in the national medical insurance catalog, a variety in the Chinese Pharmacopoeia, and a national invention patent; it has maintained the *brand position among gynecological Chinese patent medicines for ten consecutive years, and ranks first among Chinese and Western pharmaceutical enterprises in Hunan Province in terms of scale. The company's products are sold to various provinces and cities, cooperating with nearly 6,000 medical institutions, more than 1,000 chain pharmacy enterprises, and nearly 50,000 pharmacies for product marketing and brand marketing, and has 45 strategic partners. The company's vision is to become a benchmark enterprise in the field of women's health and a brand enterprise in the Chinese medicine derivative industry. The Qianjin Group's medium-term goal is to achieve annual sales of 5 billion yuan.